TrovaGene Inc (NASDAQ:TROV) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.57 and traded as high as $1.15. TrovaGene shares last traded at $1.15, with a volume of 500 shares trading hands.
Several analysts have commented on the company. Noble Financial restated a “buy” rating and issued a $23.00 price target on shares of TrovaGene in a report on Wednesday, October 2nd. ValuEngine raised TrovaGene from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of TrovaGene in a research note on Thursday, October 3rd.
The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.20 and a current ratio of 3.20. The firm has a market cap of $6.43 million, a PE ratio of -0.13 and a beta of 0.24. The stock has a fifty day moving average price of $1.72 and a 200-day moving average price of $2.54.
TrovaGene (NASDAQ:TROV) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.27). TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The firm had revenue of $0.14 million for the quarter. As a group, equities analysts predict that TrovaGene Inc will post -4.02 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the company. Wedbush Securities Inc. purchased a new stake in shares of TrovaGene during the 2nd quarter worth about $25,000. Morgan Stanley grew its holdings in shares of TrovaGene by 26,190.3% during the 2nd quarter. Morgan Stanley now owns 27,079 shares of the medical research company’s stock worth $68,000 after purchasing an additional 26,976 shares during the period. Renaissance Technologies LLC grew its holdings in shares of TrovaGene by 55.5% during the 2nd quarter. Renaissance Technologies LLC now owns 249,121 shares of the medical research company’s stock worth $623,000 after purchasing an additional 88,900 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of TrovaGene by 320.8% during the 2nd quarter. Vanguard Group Inc. now owns 285,150 shares of the medical research company’s stock worth $713,000 after purchasing an additional 217,386 shares during the period. Institutional investors and hedge funds own 10.85% of the company’s stock.
About TrovaGene (NASDAQ:TROV)
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Further Reading: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.